Accessibility Menu
Sino Biopharmaceutical logo

Sino Biopharmaceutical(OTC) SBHMY

Current Price$12.68
Market Cap$11.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+67%
5 Year-29%
1 Year-21%
1 Month+1%
Sino Biopharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 12.682026-07-24
Sino Biopharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 12.682026-07-13
1 month+1.02%USD 12.552026-06-24
3 month-9.8%USD 14.062026-04-24
Year to date-29.7%USD 18.042025-12-31
1 year-20.91%USD 16.032025-07-14
3 year+50.51%USD 8.422023-07-17
5 year-28.56%USD 17.752021-07-20
Since inception+66.67%USD 7.612017-09-05

Sino Biopharmaceutical Financials at a Glance

Market Cap

$11.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥31.83B

Net Income (TTM)

CN¥2.34B

EPS (TTM)

$0.35

P/E Ratio

35.73

Dividend

$0.26

Beta (Volatility)

0.05 (Low)

Price

$12.68

Volume

1

Open

$12.68

Previous Close

$12.68

Daily Range

$12.68 - $12.68

52-Week Range

$11.27 - $20.16

Estimated Earnings Date

Mar 18, 2026

SBHMY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a leading research and development-focused pharmaceutical company based in the People's Republic of China. The company operates through three main divisions, offering a diverse range of therapeutic products and services across various medical fields.

Products and Services
  • Oncology treatments, including Qingkeshu tablets and Leweixin injections
  • Cardiovascular and cerebrovascular medications, such as Kaina and Anrixin tablets
  • Advanced pharmaceutical agents and combination therapies for various health conditions
Growth Outlook
  • Strong demand for innovative therapies in the Chinese healthcare market
  • Expansion into new therapeutic areas and product lines anticipated
  • Investment in R&D expected to drive future revenue growth
Financial Highlights
  • Recent quarterly revenue of 7.13 billion CNY, reflecting stable performance
  • Trailing twelve months (TTM) net profit margin of 7.36%, indicating profitability
  • Dividend yield of approximately 1.90%, providing a return to shareholders
Sino Biopharmaceutical Limited has established itself as a significant player in the biotechnology sector, with a comprehensive portfolio that addresses various health needs. The company's commitment to research and development positions it well for future growth, particularly in the rapidly evolving Chinese pharmaceutical market. Recent financial performance demonstrates resilience, with a solid revenue base and a focus on innovation. Investors may find the company's strategic direction and financial stability appealing as it continues to expand its offerings and market presence.
AI Generated • Jul 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

21,435

CEO

S Y Tse

Website

www.sinobiopharm.com

Headquarters

Hong Kong, HK

SBHMY Financials

Key Financial Metrics (TTM)

Gross Margin

82.07%

Operating Margin

21.84%

Net Income Margin

7.36%

Return on Equity

7.32%

Return on Capital

14.17%

Return on Assets

3.08%

Earnings Yield

2.80%

Dividend Yield

2.02%

Payout Ratio

64.12%

Stock Overview

Market Cap

$11.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

890.72M

Volume

1

Avg. Volume

43.613

Financials (TTM)

Gross Profit

CN¥26.13B

Operating Income

CN¥6.95B

EBITDA

CN¥7.27B

Operating Cash Flow

CN¥9.29B

Capital Expenditure

-CN¥1.24B

Free Cash Flow

CN¥8.05B

Cash & ST Invst.

CN¥22.96B

Total Debt

CN¥16.07B

Sino Biopharmaceutical Performance Analysis

Sino Biopharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 3,865,053,398-7.2%
20232023-12-31CNY 3,697,855,080-4.3%
20242024-12-31CNY 4,010,960,7448.5%
20252025-12-31CNY 4,428,560,97610.4%
Sino Biopharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3135.3%
Q22025-06-30N/A
Q32025-09-30-18.9%
Q42025-12-31N/A
Sino Biopharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.36-84.1%
20232023-12-31CNY 0.36-1.6%
20242024-12-31CNY 0.27-23.5%
20252025-12-31CNY 0.3632.8%
Sino Biopharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31571.4%
Q22025-06-30N/A
Q32025-09-30-130.9%
Q42025-12-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥7.13B

+9.8%

Gross Profit

CN¥5.82B

+10.8%

Gross Margin

81.58%

N/A

Market Cap

$11.29BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$526.91K

N/A

Employees

21,435

N/A

Net Income

-CN¥522.62M

-316.6%

EBITDA

CN¥1.66B

+52.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥22.96B

+57.3%

Total Debt

CN¥16.07B

+64.3%

Accounts Receivable

CN¥7.87B

+57.0%

Inventory

CN¥2.26B

-4.9%

Long Term Debt

CN¥7.65B

+267.8%

Short Term Debt

CN¥8.42B

+9.3%

Return on Assets

3.08%

N/A

Return on Invested Capital

13.69%

N/A

Free Cash Flow

CN¥2.58B

N/A

Operating Cash Flow

CN¥3.07B

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNMSFGenmab A/S
$274.50+0.00%
SAUHYStraumann Holding AG
$11.64-1.02%
IVBXFInnovent Biologics, Inc.
$10.83-15.39%
SAUHFStraumann Holding AG
$118.30-2.99%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
SOFISoFi Technologies
$16.46-0.01%
TAT&T
$24.13+0.05%
AALAmerican Airlines Group
$14.48+0.07%

Questions About SBHMY

What is the current price of Sino Biopharmaceutical?

Sino Biopharmaceutical is trading at $12.68 per share.

What is the 52-week range for Sino Biopharmaceutical?

Over the past 52 weeks, Sino Biopharmaceutical has traded between $11.27 and $20.16.

How much debt does Sino Biopharmaceutical have?

As of the most recent reporting period, Sino Biopharmaceutical reported total debt of CN¥2.30B.

How much cash does Sino Biopharmaceutical have on hand?

Sino Biopharmaceutical reported CN¥1.06B in cash and cash equivalents in its most recent financial results.

What is Sino Biopharmaceutical’s dividend yield?

Sino Biopharmaceutical currently has a dividend yield of 2.02%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services